GlassScriptPhysician profile
Brandon L Allard
NPI 1124023882
$2,798.82
in general payments reported to CMS, 2019-2025
28 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $211 · 2021: $414 · 2022: $503 · 2023: $494 · 2024: $509 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $670.70 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $314.06 | 2019-2025 | Evenity, Prolia, Repatha |
| Insulet Corporation | $298.23 | 2019-2024 | Omnipod |
| Novo Nordisk INC | $241.35 | 2019-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $213.67 | 2021-2024 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $125.48 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.81 | 2020-2024 | Jardiance |
| Abbott Laboratories | $100.98 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $91.95 | 2019-2022 | |
| Kyowa Kirin, INC. | $84.91 | 2023-2024 | Crysvita |
| Regeneron Healthcare Solutions, INC. | $78.95 | 2019-2025 | Evkeeza |
| Medtronic Minimed, INC. | $66.25 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $53.22 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amryt Pharma Holdings LTD | $41.14 | 2022-2023 | Mycapssa |
| Janssen Pharmaceuticals, INC | $37.55 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.66 | 2020-2022 | |
| Becton, Dickinson and Company | $30.97 | 2021 | |
| Lilly USA, LLC | $27.53 | 2024 | Jardiance, Zepbound |
| Antares Pharma, INC. | $24.70 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $19.90 | 2024 | Baqsimi |
| Alvogen INC | $19.00 | 2025 | Teriparatide |
| Corcept Therapeutics | $18.21 | 2024 | Korlym |
| Ibsa Pharma INC. | $16.37 | 2023 | Tirosint, Licart |
| Sequel Med Tech, LLC | $16.27 | 2025 | Twiist |
| Radius Health, INC. | $14.48 | 2019 | |
| Beta Bionics, INC. | $14.43 | 2024 | Ilet Bionic Pancreas |
| Horizon Therapeutics Plc | $13.33 | 2022 | |
| Merck Sharp & Dohme LLC | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Allard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.